Article · 13 Feb 2026
Conference abstractPublished 23 Nov 2012
Biosimilar regulations in India: Current scenario
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Biosimilars are designated as ?Smilar Biologics? in India. EMA has clear defined guidance for the regulations of Biosimilars. US and India are developing the regulations of Biosimilars. Developing bioimilars regulatory policy is a challenge to Indian authorities because it is utmost important to create balance in between serving quality, safe drug which is affordable and has easy access to people. Currently the final draft of similar biologics regulatory policy is under review by the government and stake holders. It is expected to finalize this document in this year. Apart from recombinant therapeutic proteins, it is proposed to include vaccines and blood products under the category of Similar Biologics in India. For the regulatory approval of similar biologics in India, complete CMC (Chemistry, Manufacturing and Control) data in comparison with reference biological product (RBP) i.e. innovator product would be needed to establish the similarity. Toxicity study in relevant animal model with the same route of administration in comparison with RBP would be needed. Immunogenecity study in animals is also suggested. With respect to human studies PK &PD study in human is required. If PD marker is not there then Confirmatory Clinical trial in comparison with RBP would be needed. Immunogencity study in human is also required. Labeling of similar biologics in India would by as per the trade name given by the manufacturer. There is no clause for data exclusivity. The above mentioned regulatory requirements for approval of similar biologics in India are for the biosimilars that are manufactured in India and are marketed in India. However, if biosimilars are manufactured in India for exports purpose and not for domestic market then only CMC data establishing proof of similarity with reference biological product is needed.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Pharmaceutical Regulatory Affairs: Open Access.
Article · 11 Feb 2026
EU GMP Annex 1 of 2022: A View in Depth
Article · 11 Feb 2026
Standard Formats Used in Drug Regulatory Submissions and Software Used
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalPharmaceutical Regulatory Affairs: Open Access
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Smita S. Singhania”

